Pentixapharm Expands Supervisory Board with Endocrinologist Marcus Quinkler

Pentixapharm AG has announced the appointment of endocrinologist Prof. Dr. med. Marcus Quinkler to its Supervisory Board. This decision was made during the General Shareholder Meeting and will take effect upon the company's split-off from Eckert & Ziegler SE.

Dr. Quinkler brings expertise in primary aldosteronism, which aligns with Pentixapharm’s Phase III lead program PENTIXAFOR (PTF-302). CEO Dr. Hakim Bouterfa highlighted Quinkler's potential to advance Pentixapharm's radiopharmaceutical therapeutic and diagnostic programs.

With a strong background in internal medicine and endocrinology, Dr. Quinkler has an impressive academic record and significant contributions in his field. He has authored over 270 peer-reviewed publications and received prestigious awards like the Schoeller-Junkmann Prize.

Quinkler expressed enthusiasm for Pentixapharm's innovative CXCR4-ligand technologies, noting their promise in improving patient outcomes and cardiovascular health. He joins the board alongside Chairman Dr. Andreas Eckert, Jens Giltsch, and Dr. Harald Hasselmann.